XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor

Table 1 Tissue microarray identifies the association between XPO1 expression and clinical characteristics in neuroblastoma patients

Factors	Case No	XPO1 expression		P value
Factors	Case No	low, No. (%)	high, No. (%)	P value
Gender				0.181
Male	28	16 (57.1)	12 (42.9)
Female	36	27 (75.0)	9 (25.0)
Age (month)				0.019
≤ 18	19	17 (89.5)	2 (10.5)
> 18	45	26 (57.8)	19 (42.2)
MYCN amplification				0.016
No	35	28 (80.0)	7 (20.0)
Yes	20	9 (45.0)	11 (55.0)
Tumor stage (INSS)				< 0.001
4 s + 1 + 2	29	27 (93.1)	2 (6.9)
3 + 4	26	10 (38.5)	16 (61.5)
Pathological histotype				0.580
Neuroblastoma	23	14 (60.9)	9 (39.1)
Ganglioneuroblastoma	41	29 (70.7)	12 (29.3)
Preoperative chemotherapy				0.008
No	31	26 (83.9)	5 (16.1)
Yes	33	17 (51.5)	16 (48.5)
Death				< 0.001
No	23	22 (95.7)	1 (4.3)
Yes	29	9 (31.0)	20 (69.0)

Pearson’s chi-squared test and CMH test was used for statistical analysis; INSS International Neuroblastoma Staging System

ISSN: 1756-9966